.png)
The global biopharmaceutical sector is witnessing a significant transition as leading consumer health and nutrition companies accelerate the commercialisation of advanced microbiome-targeted therapies. In a major move to expand its clinical footprint, Nestlé Health Science has entered into a strategic licensing agreement with Milan-headquartered IdB Holding S.p.A. (IdB).
The collaboration is designed to develop and, subject to regulatory approval, commercialise VOWST (faecal microbiota spores, live-brpk) for patients across Europe.
VOWST is currently approved for sale only in the United States, where it operates as the first and only Food and Drug Administration (FDA) approved orally administered live biotherapeutic product (LBP). By partnering with a prominent European life sciences group, Nestlé Health Science is executing a targeted geographical expansion to capture first-mover advantage in the European microbiome sector.
The agreement marks a calculated effort to transition VOWST from a domestic US success story into a globally recognised clinical therapy.
VOWST
The clinical value of VOWST lies in its highly specific therapeutic indication. The oral biotherapeutic is formulated to prevent recurrent Clostridioides difficile infection (rCDI) in adults following standard antibacterial treatment.
Recurrent CDI represents a severe, potentially life-threatening gastrointestinal infection that presents substantial treatment challenges and high readmission rates for healthcare systems.
Under the newly established agreement, the two organisations will work jointly to navigate the rigorous approval process of the European Medicines Agency (EMA). For Nestlé Health Science, securing EMA clearance is a critical hurdle that requires robust clinical documentation and standardised manufacturing controls.
By utilising IdB's extensive regulatory expertise in Europe, the partnership aims to streamline the approval timeline, facilitating rapid market entry once compliance standards are met.
From a product development perspective, VOWST represents a shift away from traditional, highly invasive faecal microbiota transplant (FMT) procedures, such as colonoscopies or enemas, towards a convenient, standardised oral capsule format. This packaging and delivery innovation drastically reduces patient discomfort, lowers hospital administration costs, and simplifies the delivery of preventative care.
Collaborative Execution
While Nestlé Health Science provides the underlying scientific foundation and manufacturing oversight, IdB Holding provides the essential regional commercialisation capabilities. As a privately owned Italian life sciences group, IdB possesses deep-rooted experience in pharmaceutical development, supply chain logistics, and medical marketing across Europe.
The commercial execution of the European rollout will be supported by IdB’s diverse corporate structure, which includes two major operating companies:
Indena: A globally active ingredients specialist with physical footprints spanning Italy, France, the United States, Brazil, China, Japan, and India.
Scharper: A dedicated healthcare and pharmaceutical business operating primarily in the Italian domestic market.
To support the VOWST launch, IdB has announced plans to establish a brand-new, dedicated life sciences company. This specialised subsidiary will focus exclusively on marketing the biotherapeutic, building relationships with European category buyers, and managing the clinical distribution network.
.jpg)